Cara Therapeutics (CARA) Short Interest Ratio & Short Volume → Buy this small stock before coming AI Tidal Wave (From Chaikin Analytics) (Ad) Free CARA Stock Alerts $0.75 -0.06 (-7.41%) (As of 05/17/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Cara Therapeutics Short Interest DataCurrent Short Volume2,610,000 sharesPrevious Short Volume2,610,000 sharesChange Vs. Previous MonthNo ChangeDollar Volume Sold Short$1.96 millionShort Interest Ratio / Days to Cover4.4Last Record DateApril 30, 2024Outstanding Shares54,680,000 sharesFloat Size46,470,000 sharesShort Percent of Float5.62%Today's Trading Volume253,065 sharesAverage Trading Volume280,610 sharesToday's Volume Vs. Average90% Short Selling Cara Therapeutics ? Sign up to receive the latest short interest report for Cara Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatCARA Short Interest Over TimeCARA Days to Cover Over TimeCARA Percentage of Float Shorted Over Time Ad Chaikin AnalyticsBuy this small stock before coming AI Tidal WaveThe internet generated more wealth than any other innovation in history - creating hundreds of thousands of new millionaires in America alone. Now A.I. could do the same. But if you're buying Microsoft or NVIDIA to profit - you're missing the big picture.Get the name and ticker symbol for free - just click here. Cara Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/30/20242,610,000 shares $1.96 million No Change5.6%4.4 $0.75 4/15/20242,610,000 shares $1.85 million +1.2%5.6%4.1 $0.71 3/31/20242,580,000 shares $2.35 million +4.0%5.6%3.7 $0.91 3/15/20242,480,000 shares $2.18 million +3.8%5.3%3.1 $0.88 2/29/20242,390,000 shares $2.03 million +7.2%5.2%2.5 $0.85 2/15/20242,230,000 shares $1.33 million -11.2%4.8%2.5 $0.60 Get the Latest News and Ratings for CARA and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Cara Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 1/31/20242,510,000 shares $1.42 million +5.5%5.4%3.2 $0.57 1/15/20242,380,000 shares $1.36 million +3.0%5.1%3.1 $0.57 12/31/20232,310,000 shares $1.72 million +6.5%5.0%3.1 $0.74 12/15/20232,170,000 shares $2.67 million -38.9%4.7%3.2 $1.23 11/30/20233,550,000 shares $3.43 million +3.8%7.7%6.2 $0.97 11/15/20233,420,000 shares $3.83 million +15.2%7.4%5.6 $1.12 10/31/20232,970,000 shares $3.83 million +9.6%6.6%5 $1.29 10/15/20232,710,000 shares $3.85 million +9.7%6.0%4.1 $1.42 9/30/20232,470,000 shares $4.15 million +10.3%5.5%3.5 $1.68 9/15/20232,240,000 shares $5.24 million +44.5%5.0%2 $2.34 8/31/20231,550,000 shares $3.98 million -40.8%3.5%1.2 $2.57 8/15/20232,620,000 shares $7.86 million -24.5%5.8%1.9 $3.00 7/31/20233,470,000 shares $11.56 million -12.6%8.1%2.5 $3.33 7/15/20233,970,000 shares $11.35 million +6.7%9.3%2.9 $2.86 6/30/20233,720,000 shares $10.53 million -35.3%8.7%2.8 $2.83 6/15/20235,750,000 shares $18.57 million +12.5%13.5%5.9 $3.23 5/31/20235,110,000 shares $16.25 million +2.0%12.0%6.8 $3.18 5/15/20235,010,000 shares $20.79 million No Change11.7%6.8 $4.15 4/30/20235,010,000 shares $21.04 million +3.5%11.9%7.5 $4.20 4/15/20234,840,000 shares $20.47 million -9.4%11.4%7.5 $4.23 3/31/20235,340,000 shares $26.22 million +3.9%12.6%8.6 $4.91 3/15/20235,140,000 shares $29.61 million -6.4%12.2%8.7 $5.76 2/28/20235,490,000 shares $55.78 million -1.4%13.0%11 $10.16 2/15/20235,570,000 shares $57.71 million +3.9%13.3%15.2 $10.36 1/31/20235,360,000 shares $62.60 million +6.4%12.8%15.3 $11.68 1/15/20235,040,000 shares $54.68 million +1.6%12.0%14.1 $10.85 12/30/20224,960,000 shares $53.27 million -10.8%11.8%13.8 $10.74 12/15/20225,560,000 shares $62.11 million -0.4%13.2%16.4 $11.17 11/30/20225,580,000 shares $65.84 million -9.4%13.3%16.5 $11.80 11/15/20226,160,000 shares $69.79 million -1.8%14.7%18.1 $11.33 10/31/20226,270,000 shares $58.94 million -1.7%14.9%17.1 $9.40 10/15/20226,380,000 shares $64.82 million -3.6%15.2%16.4 $10.16 9/30/20226,620,000 shares $61.96 million -7.2%15.8%16.4 $9.36 9/15/20227,130,000 shares $73.65 million No Change17.0%16.5 $10.33Biden Nomination CANCELED? (Ad)The Hill just published that Joe Biden has received enough delegates to…“clinch the Democratic presidential nomination and all but guaranteeing he will face off against former President Trump again in November.” Why is he all BUT guaranteed the Democratic nomination, in their words?I believe I have the terrifying answer right here. CARA Short Interest - Frequently Asked Questions What is Cara Therapeutics' current short interest? Short interest is the volume of Cara Therapeutics shares that have been sold short but have not yet been covered or closed out. As of April 30th, investors have sold 2,610,000 shares of CARA short. 5.62% of Cara Therapeutics' shares are currently sold short. Learn More on Cara Therapeutics' current short interest. What is a good short interest ratio for Cara Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. CARA shares currently have a short interest ratio of 4.0. Learn More on Cara Therapeutics's short interest ratio. Which institutional investors are shorting Cara Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Cara Therapeutics: Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Cara Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 5.62% of Cara Therapeutics' floating shares are currently sold short. What is Cara Therapeutics' float size? Cara Therapeutics currently has issued a total of 54,680,000 shares. Some of Cara Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Cara Therapeutics currently has a public float of 46,470,000 shares. How does Cara Therapeutics' short interest compare to its competitors? 5.62% of Cara Therapeutics' shares are currently sold short. Here is how the short interest of companies compare to Cara Therapeutics: Lexaria Bioscience Corp. (2.29%), Xilio Therapeutics, Inc. (5.24%), Unicycive Therapeutics, Inc. (2.13%), Sensei Biotherapeutics, Inc. (0.37%), ProMIS Neurosciences, Inc. (0.05%), VYNE Therapeutics Inc. (0.68%), CASI Pharmaceuticals, Inc. (0.73%), Eyenovia, Inc. (11.45%), Gain Therapeutics, Inc. (1.02%), Marker Therapeutics, Inc. (0.84%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.98 billion), Occidental Petroleum Co. ($3.35 billion), Charter Communications, Inc. ($3.06 billion), General Motors ($2.88 billion), Moderna, Inc. ($2.32 billion), Tractor Supply ($2.27 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.18 billion), Williams-Sonoma, Inc. ($1.95 billion), and Chesapeake Energy Co. ($1.52 billion). View all of the most shorted stocks. What does it mean to sell short Cara Therapeutics stock? Short selling CARA is an investing strategy that aims to generate trading profit from Cara Therapeutics as its price is falling. CARA shares are trading down $0.06 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Cara Therapeutics? A short squeeze for Cara Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of CARA, which in turn drives the price of the stock up even further. How often is Cara Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including CARA, twice per month. The most recent reporting period available is April, 30 2024. More Short Interest Resources from MarketBeat Related Companies: LEXX Short Interest XLO Short Interest UNCY Short Interest SNSE Short Interest PMN Short Interest VYNE Short Interest CASI Short Interest EYEN Short Interest GANX Short Interest MRKR Short Interest Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:CARA) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersShocking $16T Elon Musk Crypto LeakCrypto 101 MediaBiden Nomination CANCELED?The Freeport SocietyMissed NVDA? Buy this AI stock NOWChaikin AnalyticsUrgent Nvidia WarningAltimetryCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingMost important medical advance in 100 yearsThe Oxford ClubCrypto Pioneer Says: “The last crypto bull market has begun.”InvestorPlaceProtect Your Bank Account Before It’s Too LateWeiss Ratings